Details of the Drug Reposition

General Information of This Drug (ID: DM41GRA)

• Drug Name: Ceftazidime (DM41GRA)
• Synonyms: Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
• Therapeutic Class: Antibiotics
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

7 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Staphylococcus aureus infection	DISK6PTH	N.A.	Approved	[1]
Staphylococcal pneumonia	DIS28ZSZ	N.A.	Approved	[1]
Peritonitis	DISMCMLQ	N.A.	Approved	[1]
Meningococcal meningitis	DISCKTAT	N.A.	Approved	[1]
Endometritis	DISHGJ6G	N.A.	Approved	[1]
Bacterial infection	DIS5QJ9S	1A00-1C4Z	Approved	[2]
Bacteremia	DIS6N9RZ	1A73	Approved	[1]

4 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Bacterial meningitis	DISRP9SL	N.A.	Discontinued in Phase 2	[3]
Sebocystomatosis	DISS9YGD	N.A.	Discontinued in Phase 2	[4]
Escherichia coli infection	DISPP65M	1A03	Discontinued in Phase 2	[5]
Bacterial pneumonia	DISPW7PH	CA40.0	Discontinued in Phase 2	[6]

2 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Rhinoscleroma	DISNSWVK	N.A.	Discontinued in Phase 1	[7]
Bacterial urinary tract infection	DISNNJTF	N.A.	Discontinued in Phase 1	[8]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pelvic inflammatory disease	DISWQR4J	GA05	Investigative	[1]

References

• [1] Ceftazidime FDA Label
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Vitamin E and C to Slow Progression of Common Carotid Artery Plaque Build-Up
• [4] Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
• [5] Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
• [6] Zonisamide for Heavy Drinkers With Bipolar Disorder
• [7] Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
• [8] Methamphetamine-Quetiapine Interactions in Humans